Company performance
Add to research
Current Price
as of Feb 14, 2025$0.29
P/E Ratio
N/A
Market Cap
$13.4M
Description
Add to research
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
Metrics
Add to research
Overview
- HQFlorham Park, NJ
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerCLRB
- Price$0.2908+3.49%
Trading Information
- Market cap$13.40M
- Float98.14%
- Average Daily Volume (1m)1,370,650
- Average Daily Volume (3m)2,817,087
- EPS-$1.71
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$14.66M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$13.26M
- EV$65.43M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B7.61
- Debt/Equity3.10
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset